Raptor Pharmaceutical Corp.  

(Public, NASDAQ:RPTP)   Watch this stock  
Find more results for William D. Keltner
5.89
-0.03 (-0.51%)
After Hours: 5.89 0.00 (0.00%)
Jul 29, 4:48PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.81 - 6.04
52 week 2.94 - 14.87
Open 6.04
Vol / Avg. 473,320.00/541,327.00
Mkt cap 484.45M
P/E     -
Div/yield     -
EPS -1.04
Shares 85.31M
Beta 1.32
Inst. own 64%
Aug 4, 2016
Q2 2016 Raptor Pharmaceutical Corp Earnings Call - 4:30PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Raptor Pharmaceutical Corp Earnings Release - 4:00PM EDT - Add to calendar
Jun 21, 2016
Raptor Pharmaceutical Corp at JMP Securities Life Sciences Conference
May 18, 2016
Raptor Pharmaceutical Corp Annual Shareholders Meeting (Estimated)
May 5, 2016
Q1 2016 Raptor Pharmaceutical Corp Earnings Call - Webcast
May 5, 2016
Q1 2016 Raptor Pharmaceutical Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -151.38% -69.21%
Operating margin -131.55% -51.42%
EBITD margin - -49.70%
Return on average assets -42.37% -21.30%
Return on average equity -170.60% -78.52%
Employees 158 -
CDP Score - -

Address

7 Hamilton Lndg Ste 100
NOVATO, CA 94949-8246
United States - Map
+1-415-4086200 (Phone)
+1-415-3828002 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.

Officers and directors

Llew Keltner Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Julie Anne Smith President, Chief Executive Officer Designate, Director
Age: 44
Bio & Compensation  - Reuters
Michael P. Smith Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Robert H. Uhl Managing Director
Bio & Compensation  - Reuters
David A Happel Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Krishna R. Polu M.D. Chief Medical Officer
Age: 41
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Gregg A. Lapointe CPA Director
Age: 56
Bio & Compensation  - Reuters
Christopher M. Starr Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Raymond William Anderson Independent Director
Age: 73
Bio & Compensation  - Reuters